{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["73(9)"],"submitter":["Singh P"],"pubmed_abstract":["Purpose
To evaluate the efficacy and safety of 1.25% pilocarpine compared to placebo for the treatment of presbyopia.Methods
This multicenter, randomized, double-masked clinical trial compared pilocarpine 1.25% to placebo in presbyopic individuals aged 45-55 years, meeting standard near vision impairment criteria. Participants were randomized 1:1 using a computer-generated sequence, with identical, unmarked bottles ensuring masking. Distance-corrected near visual acuity (DCNVA) and distance-corrected intermediate visual acuity (DCIVA) were assessed under mesopic and photopic conditions across multiple visits (days 1, 3, 7, 14, and 30). The primary outcome was a ≥ 3-line gain in mesopic, high-contrast, binocular DCNVA at day 30, hour 3. Secondary outcomes included photopic a"],"journal":["Indian journal of ophthalmology"],"pagination":["1251-1257"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12448526"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and safety of pilocarpine hydrochloride ophthalmic solution USP 1.25% w/v versus placebo ophthalmic solution for the treatment of presbyopia - A multicentric clinical trial."],"pmcid":["PMC12448526"],"pubmed_authors":["Datta A","Nivean M","Garasiya T","Singh P","Ajila V","Sengupta S"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and safety of pilocarpine hydrochloride ophthalmic solution USP 1.25% w/v versus placebo ophthalmic solution for the treatment of presbyopia - A multicentric clinical trial.","description":"Purpose
To evaluate the efficacy and safety of 1.25% pilocarpine compared to placebo for the treatment of presbyopia.Methods
This multicenter, randomized, double-masked clinical trial compared pilocarpine 1.25% to placebo in presbyopic individuals aged 45-55 years, meeting standard near vision impairment criteria. Participants were randomized 1:1 using a computer-generated sequence, with identical, unmarked bottles ensuring masking. Distance-corrected near visual acuity (DCNVA) and distance-corrected intermediate visual acuity (DCIVA) were assessed under mesopic and photopic conditions across multiple visits (days 1, 3, 7, 14, and 30). The primary outcome was a ≥ 3-line gain in mesopic, high-contrast, binocular DCNVA at day 30, hour 3. Secondary outcomes included photopic a","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-07-12T03:16:09.449Z","creation":"2026-07-12T03:09:16.421Z"},"accession":"S-EPMC12448526","cross_references":{"pubmed":["40880143"],"doi":["10.4103/IJO.IJO_680_25"]}}